2027 ICD-10-CM Diagnosis Code T38.5X5AAdverse effect of other estrogens and progestogens, initial encounter

ICD-10-CM Codes›S00–T88›T36-T50›T38

ICD-10-CM T38.5X5A
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

T38.5X5A is a billable ICD-10-CM diagnosis code for adverse effect of other estrogens and progestogens, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 791, 793, 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T38.5X5A
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of other estrogens and progestogens, initial encounter
Short Description
Adverse effect of oth estrogens and progestogens, init
Parent Code
Adverse effect of other estrogens and progestogens

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT38Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
This CodeT38.5X5AAdverse effect of other estrogens and progestogens, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T38.5X5A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • 46,XX disorder of sex development caused by synthetic oral diethylstilbestrol
  • 46,XX disorder of sex development caused by synthetic oral progestogen
  • Adverse reaction to cyproterone and/or ethinyl estradiol
  • Adverse reaction to estrogen and/or progesterone
  • Adverse reaction to polyestradiol
  • Allylestrenol adverse reaction
  • Autoimmune progesterone dermatitis
  • Clomiphene adverse reaction
  • Conjugated estrogens adverse reaction
  • Dienestrol adverse reaction
  • Dydrogesterone adverse reaction
  • Endometriosis of spermatic cord following estrogen therapy
  • Estradiol adverse reaction
  • Estradiol implant adverse reaction
  • Estriol adverse reaction
  • Estrogen adverse reaction
  • Estrogen antagonist adverse reaction
  • Ethinylestradiol adverse reaction
  • Fetal disorder caused by diethylstilbestrol transmitted via placenta
  • Fosfestrol adverse reaction
  • Gestrinone adverse reaction
  • Gestronol adverse reaction
  • HRT side-effects
  • Hydroxyprogesterone adverse reaction
  • Medroxyprogesterone adverse reaction
  • Megestrol adverse reaction
  • Menopause monitoring status
  • Mestranol adverse reaction
  • Oral estradiol adverse reaction
  • Piperazine estrone sulfate adverse reaction
  • Progesterone adverse reaction
  • Progestogen adverse reaction
  • Quinestradol adverse reaction
  • Quinestrol adverse reaction
  • Stilbestrol adverse reaction
  • Stilbestrol-related vaginal adenosis
  • Topical estradiol adverse reaction
  • Vaginal adenosis

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027, published by CMS and the National Center for Health Statistics.

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to T38.5X5A: its own notes plus those printed at T38, block T36-T50, and Chapter 19. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • adverse effect of correct substance properly administered
  • poisoning by overdose of substance
  • poisoning by wrong substance given or taken in error
  • underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified applies to 234 codes
  • mineralocorticoids and their antagonists (T50.0-)
  • oxytocic hormones (T48.0-)
  • parathyroid hormones and derivatives (T50.9-)
From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • toxic reaction to local anesthesia in pregnancy (O29.3-)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • abuse and dependence of psychoactive substances (F10-F19)
  • abuse of non-dependence-producing substances (F55.-)
  • immunodeficiency due to drugs (D84.821)
  • drug reaction and poisoning affecting newborn (P00-P96)
  • pathological drug intoxication (inebriation) (F10-F19)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes

Code First

The underlying condition named in the note is sequenced before this code.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • for adverse effects, the nature of the adverse effect, such as:
  • adverse effect NOS (T88.7)
  • aspirin gastritis (K29.-)
  • blood disorders (D56-D76)
  • contact dermatitis (L23-L25)
  • dermatitis due to substances taken internally (L27.-)
  • nephropathy (N14.0-N14.2)

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • code(s) to specify:
  • manifestations of poisoning
  • underdosing or failure in dosage during medical and surgical care (Y63.6, Y63.8-Y63.9)
  • underdosing of medication regimen (Z91.12-, Z91.13-)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • code to identify any retained foreign body, if applicable (Z18.-)

Notes

General instructions on how these codes are used.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
  • The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.

7th Character

Every code in the category takes a 7th character from the listed values, with the placeholder X filling any empty positions before it.

From T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified applies to 234 codes
  • The appropriate 7th character is to be added to each code from category T38
  • Ainitial encounter this code
  • Dsubsequent encounter
  • Ssequela

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name T38.5X5A, its category, or a range that includes it.

Excludes1 1

These codes carry an Excludes1 note naming T38.5X5A: they are not reported together with it, unless the two conditions are unrelated.

  • T48.0 Poisoning by, adverse effect of and underdosing of oxytocic drugs
    poisoning by, adverse effect of and underdosing of estrogens, progestogens and antagonists (T38.4-T38.6) names T38.4-T38.6, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ028
Adverse effects of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient Yes

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AllylestrenolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Anhydrohydroxy-progesteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Antineoplastic NEC::combination::estrogenT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ChlormadinoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ChlorotrianiseneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ChlortrianiseneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ClomifeneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ClomipheneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Conjugated estrogenic substancesT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DelalutinT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DemegestoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DesogestrelT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DiaethylstilboestrolumT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DienestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DienoestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Diethyl::stilbestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DiethylstilbestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DiethylstilboestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DimestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DimethisteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
DydrogesteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EpiestriolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EpimestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EstradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Estradiol::benzoateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EstriolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EstrogenT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Estrogen::with progesteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Estrogen::conjugatedT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EstroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EstropipateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Ethinylestradiol, ethinyloestradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
EthisteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
FosfestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Gestonorone caproateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Gonadal tissue extract::femaleT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
HexestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
HexoestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Hormone::ovarianT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
HydroxyestroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
HydroxyprogesteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Hydroxyprogesterone::caproateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
IsopregnenoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Levonorgestrel::with ethinylestradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Lipo-LutinT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
LutocylolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
LutromoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MedrogestoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Medroxyprogesterone acetate (depot)T38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MegestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MestranolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MethallenestrilT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MethallenoestrilT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
MethylestrenoloneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
NomegestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Norethisterone (acetate) (enantate)::with ethinylestradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
NoretynodrelT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
NormethandroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
OestradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
OestriolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
OestrogenT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
OestroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Ovarian::hormoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Ovarian::stimulantT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
OxendoloneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Piperazine::estrone sulfateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Polyestradiol phosphateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Polyoestradiol phosphateT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
PregnandiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
PregneninoloneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
PremarinT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ProgesteroneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ProgestinT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Progestogen NECT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ProgestoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ProlutonT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
PromegestoneT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
ProveraT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
QuinestradiolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
QuinestradolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
QuinestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
Steroid::antineoplastic, hormone::estrogenT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
StilbestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
StilboestrolT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6
TaceT38.5X1T38.5X2T38.5X3T38.5X4T38.5X5T38.5X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T38.5X5A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
995.29 Adv eff med/biol NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E932.2 Adv eff ovarian hormones
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About T38.5X5AOverview

What is the ICD-10 code for adverse effect of other estrogens and progestogens, initial encounter?

The ICD-10-CM code for adverse effect of other estrogens and progestogens, initial encounter is T38.5X5A (sometimes written as T385X5A). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is T38.5X5A (Adverse effect of other estrogens and progestogens) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other estrogens and progestogens, initial encounter on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What does the 7th character A in T38.5X5A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of other estrogens and progestogens, such as an emergency visit or first evaluation.

What MS-DRG does T38.5X5A group to?

On inpatient claims, adverse effect of other estrogens and progestogens, initial encounter maps to MS-DRG 793, 791, 918, 917, with relative weights from 0.8716 to 4.2192 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T38.5X5A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other estrogens and progestogens, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.